4 completed, 2 unknown, 1 terminated. 5 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 3 | Unknown 2, Terminated 1 |
Follow DPI-386 Nasal Gel: new trials by email Literature Review of DPI-386 Nasal Gel trials Research Report on DPI-386 Nasal Gel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion DPI-386 Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 503 | 2022-08-23 | 2023-03-21 |
| Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance DPI-386 Nasal Gel, Placebo Nasal Gel - Motion Sickness, Space, Motion Sickness | Phase 2 | Unknown | Repurposed Therapeutics, Inc. | 30 | 2022-01-21 | 2024-05-17 |
| Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine) - Motion Sickness, Space, Motion Simulation | Phase 2 | Unknown | Repurposed Therapeutics, Inc. | 80 | 2021-08-10 | 2024-05-16 |
| Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion DPI-386 Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 140 | 2021-06-14 | 2021-09-17 |
| Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, Placebos - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 102 | 2019-06-09 | 2019-12-03 |
| Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects Scopolamine, Placebo Nasal Gel - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 98 | 2019-06-07 | 2023-05-06 |
| DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop® - Motion Sickness | Phase 2 / Phase 3 | Terminated | Repurposed Therapeutics, Inc. | 23 | 2018-06-29 | 2020-01-07 |
Motion Sickness (6) · Space Motion Sickness (2)
Repurposed Therapeutics, Inc. (7)
United States (7)
David Helton (3) · David R Helton (2) · Scott J Wood, PhD (2)